company background image
IRWD logo

Ironwood Pharmaceuticals NasdaqGS:IRWD Stock Report

Last Price

US$15.07

Market Cap

US$2.4b

7D

3.4%

1Y

32.0%

Updated

24 Feb, 2024

Data

Company Financials +

Ironwood Pharmaceuticals, Inc.

NasdaqGS:IRWD Stock Report

Market Cap: US$2.4b

IRWD Stock Overview

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.

IRWD fundamental analysis
Snowflake Score
Valuation6/6
Future Growth4/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Ironwood Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ironwood Pharmaceuticals
Historical stock prices
Current Share PriceUS$15.07
52 Week HighUS$15.70
52 Week LowUS$8.08
Beta0.63
1 Month Change11.22%
3 Month Change56.82%
1 Year Change31.96%
3 Year Change63.27%
5 Year Change1.76%
Change since IPO29.36%

Recent News & Updates

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Feb 16
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Recent updates

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Feb 16
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Jan 31

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Dec 19
Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Jul 25
Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Apr 18
An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Mar 28
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Ironwood Pharmaceuticals: Rinse, Wash And Repeat

Oct 05

These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Sep 28
These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh

Jul 29

Ironwood Pharmaceuticals: Undervalued Company With Steady Growth

Sep 27

Here's Why I Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Might Deserve Your Attention Today

Jul 21
Here's Why I Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Might Deserve Your Attention Today

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Jun 22
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Ironwood Pharmaceuticals names Thomas McCourt permanent CEO

Jun 07

Ironwood Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 10

Shareholder Returns

IRWDUS BiotechsUS Market
7D3.4%1.5%1.3%
1Y32.0%10.5%25.6%

Return vs Industry: IRWD exceeded the US Biotechs industry which returned 8.1% over the past year.

Return vs Market: IRWD exceeded the US Market which returned 23.3% over the past year.

Price Volatility

Is IRWD's price volatile compared to industry and market?
IRWD volatility
IRWD Average Weekly Movement5.3%
Biotechs Industry Average Movement11.4%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: IRWD's share price has been volatile over the past 3 months.

Volatility Over Time: IRWD's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998267Tom McCourthttps://www.ironwoodpharma.com

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis.

Ironwood Pharmaceuticals, Inc. Fundamentals Summary

How do Ironwood Pharmaceuticals's earnings and revenue compare to its market cap?
IRWD fundamental statistics
Market capUS$2.36b
Earnings (TTM)-US$1.00b
Revenue (TTM)US$442.74m

5.3x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IRWD income statement (TTM)
RevenueUS$442.74m
Cost of RevenueUS$116.09m
Gross ProfitUS$326.65m
Other ExpensesUS$1.33b
Earnings-US$1.00b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-6.40
Gross Margin73.78%
Net Profit Margin-226.37%
Debt/Equity Ratio-201.5%

How did IRWD perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.